Author Archives: Charles Moore

Vertex Announces Significant Progress in Development Efforts to Treat Cause of Cystic Fibrosis in Most People With the Disease

Vertex Pharmaceuticals Incorporated is a global biotechnology company whose corporate mission is to discover, develop and commercialize innovative medicines that can help people with serious diseases lead better lives. Vertex initiated its CF research program in 1998 as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT),…

Synedgen Presents New CF Complication Treatment Options at North American Cystic Fibrosis Conference

Researchers at Claremont, California-based biotechnology company Synedgen are developing targeted therapies that address complications of cystic fibrosis (CF) on pulmonary and GI surfaces for which only limited treatment options are currently available — an unmet need frequently leading to early mortality. CF is a genetic disease caused by mutations in…

Phase 1b Results for N91115 Cystic Fibrosis Drug Presented at the North American Cystic Fibrosis Conference

Boulder, Colorado based Nivalis Therapeutics, Inc. a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), is reporting positive topline results from a Phase 1b clinical study evaluating its Cystic Fibrosis drug candidate N91115 — a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR)…

Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections

Flemington, New Jersey based clinical stage biopharmaceutical company Arno Therapeutics, Inc. has announced data from a preclinical study demonstrating that its drug candidate AR-13, an analogue of Arno’s AR-12 infectious disease compound portfolio, shows promise as a potential new therapeutic option for patients with cystic fibrosis (CF) who are…

Cystic Fibrosis Foundation Expert Testifies In Support of Congressional Ensuring Access to Clinical Trials Act

Johns Hopkins University Hospital physician and Cystic Fibrosis Foundation Vice President of Therapeutics Development Michael Boyle, M.D., testified on Friday, September 18th before the House Energy and Commerce Committee’s on Health, urging Subcommittee members to support Bill H.R. 209, which would make a permanent the Ensuring Access to Clinical…


Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.